Cargando…

Induction versus adjuvant chemotherapy combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study

Background: Currently available evidence favors the combination of chemotherapy with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma (LANPC). However, the optimal timing for additional chemotherapy is unclear. This study was conducted to compare the efficacy and toxi...

Descripción completa

Detalles Bibliográficos
Autores principales: Mu, Xiaoli, Liu, Hongyan, Wu, Juan, Chen, Shi, Peng, Xingchen, Wang, Jingjing, Wei, Zhigong, He, Ling, Liu, Jiyan, Lu, Zejun, Su, Yonglin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9467407/
https://www.ncbi.nlm.nih.gov/pubmed/36036759
http://dx.doi.org/10.18632/aging.204246
_version_ 1784788188110258176
author Mu, Xiaoli
Liu, Hongyan
Wu, Juan
Chen, Shi
Peng, Xingchen
Wang, Jingjing
Wei, Zhigong
He, Ling
Liu, Jiyan
Lu, Zejun
Su, Yonglin
author_facet Mu, Xiaoli
Liu, Hongyan
Wu, Juan
Chen, Shi
Peng, Xingchen
Wang, Jingjing
Wei, Zhigong
He, Ling
Liu, Jiyan
Lu, Zejun
Su, Yonglin
author_sort Mu, Xiaoli
collection PubMed
description Background: Currently available evidence favors the combination of chemotherapy with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma (LANPC). However, the optimal timing for additional chemotherapy is unclear. This study was conducted to compare the efficacy and toxicity of induction chemotherapy plus concurrent chemoradiotherapy (IC+CCRT) versus concurrent chemoradiotherapy plus adjuvant chemotherapy (CCRT+AC). Methods: Two medical centers in China enrolled patients with LANPC (stage III-IVB) between January 2009 and May 2020. Through the use of propensity score matching (PSM), baseline characteristics were balanced. The primary endpoint was overall survival (OS), which was evaluated by the Kaplan-Meier method and log-rank test. Potential independent prognostic factors were identified using univariate and multivariate Cox proportional hazard analyses. Based on the chi-squared test, we compared the adverse events associated with treatment between the groups. Results: After the implementation of PSM, 159 patients treated with IC+CCRT and 72 patients treated with CCRT+AC were eventually enrolled in this study. There was no significant difference between patients treated with IC+CCRT and CCRT+AC in terms of 3-year OS (94.7% versus 90.9%, p=0.816), progression-free survival (PFS) (91.2% versus 83.1%, p=0.588), locoregional recurrence-free survival (LRFS) (92.5% versus 81.8%, p=0.478), or distant metastasis-free survival (DMFS) (93.4% versus 88.2%, p=0.783). There was no prognostic significance of the treatment for OS, PFS, LRFS, or DMFS (all p > 0.05) in the univariate and multivariate analyses. Patients treated with CCRT+AC had a higher incidence of grade 3 to 4 leucopenia (p=0.001) and neutropenia (p=0.001) than those treated with IC+CCRT. Conclusions: IC plus CCRT achieved comparable survival outcomes to CCRT plus AC and had a lower incidence of toxicity.
format Online
Article
Text
id pubmed-9467407
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Impact Journals
record_format MEDLINE/PubMed
spelling pubmed-94674072022-09-14 Induction versus adjuvant chemotherapy combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study Mu, Xiaoli Liu, Hongyan Wu, Juan Chen, Shi Peng, Xingchen Wang, Jingjing Wei, Zhigong He, Ling Liu, Jiyan Lu, Zejun Su, Yonglin Aging (Albany NY) Research Paper Background: Currently available evidence favors the combination of chemotherapy with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma (LANPC). However, the optimal timing for additional chemotherapy is unclear. This study was conducted to compare the efficacy and toxicity of induction chemotherapy plus concurrent chemoradiotherapy (IC+CCRT) versus concurrent chemoradiotherapy plus adjuvant chemotherapy (CCRT+AC). Methods: Two medical centers in China enrolled patients with LANPC (stage III-IVB) between January 2009 and May 2020. Through the use of propensity score matching (PSM), baseline characteristics were balanced. The primary endpoint was overall survival (OS), which was evaluated by the Kaplan-Meier method and log-rank test. Potential independent prognostic factors were identified using univariate and multivariate Cox proportional hazard analyses. Based on the chi-squared test, we compared the adverse events associated with treatment between the groups. Results: After the implementation of PSM, 159 patients treated with IC+CCRT and 72 patients treated with CCRT+AC were eventually enrolled in this study. There was no significant difference between patients treated with IC+CCRT and CCRT+AC in terms of 3-year OS (94.7% versus 90.9%, p=0.816), progression-free survival (PFS) (91.2% versus 83.1%, p=0.588), locoregional recurrence-free survival (LRFS) (92.5% versus 81.8%, p=0.478), or distant metastasis-free survival (DMFS) (93.4% versus 88.2%, p=0.783). There was no prognostic significance of the treatment for OS, PFS, LRFS, or DMFS (all p > 0.05) in the univariate and multivariate analyses. Patients treated with CCRT+AC had a higher incidence of grade 3 to 4 leucopenia (p=0.001) and neutropenia (p=0.001) than those treated with IC+CCRT. Conclusions: IC plus CCRT achieved comparable survival outcomes to CCRT plus AC and had a lower incidence of toxicity. Impact Journals 2022-08-26 /pmc/articles/PMC9467407/ /pubmed/36036759 http://dx.doi.org/10.18632/aging.204246 Text en Copyright: © 2022 Mu et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Mu, Xiaoli
Liu, Hongyan
Wu, Juan
Chen, Shi
Peng, Xingchen
Wang, Jingjing
Wei, Zhigong
He, Ling
Liu, Jiyan
Lu, Zejun
Su, Yonglin
Induction versus adjuvant chemotherapy combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study
title Induction versus adjuvant chemotherapy combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study
title_full Induction versus adjuvant chemotherapy combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study
title_fullStr Induction versus adjuvant chemotherapy combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study
title_full_unstemmed Induction versus adjuvant chemotherapy combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study
title_short Induction versus adjuvant chemotherapy combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study
title_sort induction versus adjuvant chemotherapy combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9467407/
https://www.ncbi.nlm.nih.gov/pubmed/36036759
http://dx.doi.org/10.18632/aging.204246
work_keys_str_mv AT muxiaoli inductionversusadjuvantchemotherapycombinedwithconcurrentchemoradiotherapyinlocoregionallyadvancednasopharyngealcarcinomaaretrospectivecohortstudy
AT liuhongyan inductionversusadjuvantchemotherapycombinedwithconcurrentchemoradiotherapyinlocoregionallyadvancednasopharyngealcarcinomaaretrospectivecohortstudy
AT wujuan inductionversusadjuvantchemotherapycombinedwithconcurrentchemoradiotherapyinlocoregionallyadvancednasopharyngealcarcinomaaretrospectivecohortstudy
AT chenshi inductionversusadjuvantchemotherapycombinedwithconcurrentchemoradiotherapyinlocoregionallyadvancednasopharyngealcarcinomaaretrospectivecohortstudy
AT pengxingchen inductionversusadjuvantchemotherapycombinedwithconcurrentchemoradiotherapyinlocoregionallyadvancednasopharyngealcarcinomaaretrospectivecohortstudy
AT wangjingjing inductionversusadjuvantchemotherapycombinedwithconcurrentchemoradiotherapyinlocoregionallyadvancednasopharyngealcarcinomaaretrospectivecohortstudy
AT weizhigong inductionversusadjuvantchemotherapycombinedwithconcurrentchemoradiotherapyinlocoregionallyadvancednasopharyngealcarcinomaaretrospectivecohortstudy
AT heling inductionversusadjuvantchemotherapycombinedwithconcurrentchemoradiotherapyinlocoregionallyadvancednasopharyngealcarcinomaaretrospectivecohortstudy
AT liujiyan inductionversusadjuvantchemotherapycombinedwithconcurrentchemoradiotherapyinlocoregionallyadvancednasopharyngealcarcinomaaretrospectivecohortstudy
AT luzejun inductionversusadjuvantchemotherapycombinedwithconcurrentchemoradiotherapyinlocoregionallyadvancednasopharyngealcarcinomaaretrospectivecohortstudy
AT suyonglin inductionversusadjuvantchemotherapycombinedwithconcurrentchemoradiotherapyinlocoregionallyadvancednasopharyngealcarcinomaaretrospectivecohortstudy